Literature DB >> 17014676

Elucidating the mechanism of wound contraction: rapid versus sustained myosin ATPase activity in attached-delayed-released compared with free-floating fibroblast-populated collagen lattices.

H Paul Ehrlich1, Bonnie Sun, Koijan S Kainth, Fatuma Kromah.   

Abstract

Wound contraction closes open wounds by the generation of contractile forces within granulation tissue. We investigated the mechanism of wound contraction using the in vitro fibroblast-populated collagen lattice (FPCL) contraction model. The contraction of the free-floating (FF)-FPCL is through rapid myosin ATPase activity, while the contraction of the attached-delayed-released (ADR)-FPCL is through sustained myosin ATPase activity. All FPCLs were cast identically and the contraction of FF-FPCLs was recorded daily for 4 days and the contraction of ADR-FPCLs was recorded 1 hour after release on day 4. At day, 4 cell numbers were determined and cells undergoing apoptosis were identified and counted. Differences in sustained and rapid myosin ATPase activity were shown by added inosine triphosphate-induced cell contraction in permeabilized fibroblast monolayer preparations. At 2 days, the FF-FPCLs were mostly contracted, while an ADR-FPCL completed contraction 1 hour after release at day 4. Contracted myofibroblasts, identified by alpha-smooth muscle actin-stained stress fibers, were identified in contracted ADR-FPCL, whereas elongated fibroblasts were identified in contracted FF-FPCLs. Vanadate inhibited both inosine triphosphate-induced cell contraction and ADR-FPCL contraction, but neither inhibited ATP-induced cell contraction or FF-FPCL contraction. Genistein inhibited FF-FPCL contraction, but not ADR-FPCL contraction. Advancing tyrosine phosphorylation in fibroblasts promotes rapid myosin ATPase activity, while advancing tyrosine dephosphorylation in myofibroblasts promotes sustained myosin ATPase. The ADR-FPCL had a reduced cell count and a greater proportion of cells had entered apoptosis compared with FF-FPCL. These experiments show that FF-FPCL contraction is through elongated fibroblasts and rapid myosin ATPase, requiring tyrosine phosphorylation. In contrast, the mechanism for ADR-FPCL contraction is through cell contraction by sustained myosin ATPase, involving tyrosine dephosphorylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17014676     DOI: 10.1111/j.1743-6109.2006.00170.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  6 in total

1.  Differences in the mechanism of collagen lattice contraction by myofibroblasts and smooth muscle cells.

Authors:  J C Dallon; H Paul Ehrlich
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

2.  Use of organotypic coculture to study keloid biology.

Authors:  Paris D Butler; Daphne P Ly; Michael T Longaker; George P Yang
Journal:  Am J Surg       Date:  2008-02       Impact factor: 2.565

Review 3.  Collagen Organization Critical Role in Wound Contraction.

Authors:  H Paul Ehrlich; Thomas K Hunt
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-02       Impact factor: 4.730

4.  Temporal spatial expression and function of non-muscle myosin II isoforms IIA and IIB in scar remodeling.

Authors:  Jennifer E Bond; Trung Q Ho; Maria Angelica Selim; Cedric L Hunter; Edith V Bowers; Howard Levinson
Journal:  Lab Invest       Date:  2010-11-22       Impact factor: 5.662

5.  Modulation of wound contracture alpha-smooth muscle actin and multispecific vitronectin receptor integrin alphavbeta3 in the rabbit's experimental model.

Authors:  Cynthia G El Kahi; Bishara S Atiyeh; Inaya Abdallah Hajj Hussein; Rosalyne Jurjus; Saad A Dibo; Alice Jurjus; Abdo Jurjus
Journal:  Int Wound J       Date:  2009-06       Impact factor: 3.315

6.  The Pro-Fibrotic Behavior of Human Tenon's Capsule Fibroblasts in Medically Treated Glaucoma Patients.

Authors:  Charles B Trelford; James T Denstedt; James J Armstrong; Cindy M L Hutnik
Journal:  Clin Ophthalmol       Date:  2020-05-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.